Zotac's MEK1 Gaming PC. Check out all of our CES 2018 Coverage: <a href="https://www.thinkcomputers.org/tag/ces-2018/">https://www.thinkcomputers.org/tag/ces-2018/</a ...

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key ...

Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided ...

Researchers from the University of Muenster described the preclinical efficacy of zapnometinib, a selective MEK1/2 inhibitor, against H5N1 clade 2.3.4.4b.

The advent of T-cell receptor (TCR) sequencing offers a transformative lens to unravel these challenges, spotlighting tumor-immune interactions and adaptive immune mechanisms pivotal to advancing ...

Called the Hyundai Elantra N TCR Edition, it's inspired by the Elantra N that competes in the Touring Car Racing (TCR) series. TCR vehicles are usually production-based sport compacts from a ...

The TCR Edition is set to launch in South Korea in December 2024, with global markets, including North America, expected to follow in 2025. Pricing details for the U.S. market have yet to be ...

Hyundai has dialed up the performance on its already spirited Elantra N sport sedan by launching a version inspired by the car's racing sibling that was designed to meet the TCR touring car ...

Now, Hyundai’s N division is dialing up the theatrics with the Elantra N TCR Edition, a special model inspired by its Touring Car Racing (TCR) World Tour sibling. Named the Elantra TCR Edition ...

Unlike chimeric antigen receptor (CAR) T-cell therapies, which can identify surface antigens, TCR-T cell therapies like Tecelra can recognize intracellular antigens presented by primary ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers ...